Pathology News

Novartis Ireland celebrated its new global collaboration with Dublin-based digital pathology company Deciphex at a panel discussion focused on the role of Artificial Intelligence (AI) in positioning Ireland as a European AI hub. The event, officiated by Minister of State for Digital, Dara Calleary TD, brought together representatives from Novartis, Deciphex, IDA Ireland, and the patient advocacy group IPPOSI. The collaboration aims to leverage advanced AI technologies to enhance preclinical research efficiency, improve accuracy, and accelerate drug discovery and development. Novartis expressed gratitude to Minister Calleary and all contributors for their valuable insights on the future of AI in healthcare and highlighted the achievements of their AI team in Elm Park. 🔗 https://lnkd.in/eimCXWkF

Pathology News is excited to feature a groundbreaking study from Wesleyan University (USA) and Gachon University Gil Medical Center (Korea), where researchers have developed a deep learning framework to predict mismatch repair deficiency (MMR-D) directly from digitized pathology slides of endometrial cancer patients. MMR-D, a subtype affecting over 30% of endometrial cancer cases, is characterized by microsatellite instability, making it highly responsive to immunotherapy. The deep learning model trained on 1,168 WSIs demonstrated strong predictive accuracy, highlighting its potential to replace time-consuming molecular testing methods with faster diagnostic solutions that improve treatment timelines. While the findings are promising, researchers emphasize the need for further validation across external datasets to ensure clinical utility. This study marks a significant step toward integrating AI into pathology workflows, with implications for diagnosing other cancer subtypes and advancing precision oncology. Stay tuned as Pathology News continues to cover innovations shaping the future of the field, and read the full article now on Pathology News: https://lnkd.in/eqs69vaU #digitalpathology #pathologynews

🔬 Owkin at SABCS 2024: Pioneering Precision Medicine in Oncology Pathology News is excited to highlight Owkin's participation at the San Antonio Breast Cancer Symposium (SABCS) 2024! Visit them at Booth #1155 to learn how they are transforming cancer research through cutting-edge artificial intelligence and groundbreaking scientific innovation. Owkin is the first end-to-end AI biotech dedicated to understanding complex biology and ensuring that every patient gets the right treatment. By combining advanced causal AI with wet lab experiments, they are identifying precision therapeutics, accelerating and de-risking clinical trials, and developing diagnostics. Their contributions extend to oncology, cardiovascular diseases, immunity, and inflammation, all powered by a robust feedback loop of discovery and innovation. 📍 Booth #1155 – Stop by and discover how Owkin is advancing the fight against breast cancer! #digitalpathology #pathologynews #SABCS2024 #Owkin #CancerResearch #AIinHealthcare #PrecisionMedicine #BreastCancerResearch

Deep Bio Inc. has partnered with PathAI to integrate its AI-powered prostate cancer diagnostic tool, DeepDx Prostate, with PathAI’s AISight®1 Image Management System (IMS). DeepDx Prostate is a CE-marked, clinically validated solution that analyzes H&E-stained prostate specimen slides, providing detailed diagnostic metrics crucial for cancer diagnosis, prognosis, and treatment planning. PathAI’s AISight IMS is a cloud-based digital pathology platform used globally by laboratories and research centers to streamline workflows and incorporate advanced AI tools. The collaboration aims to enhance prostate cancer diagnostics by combining Deep Bio’s AI expertise with PathAI’s platform, expanding access to these tools for clinicians in North America and Europe. This partnership aligns with both companies' goals to improve diagnostic precision, workflow efficiency, and patient outcomes, while advancing digital pathology and AI-powered cancer diagnostics worldwide. Read the full press release on Pathology News: https://lnkd.in/ekF6i5bc #digitalpathology #pathologynews

Proscia®, a leader in AI-enabled pathology solutions, was recognized in Fast Company’s Next Big Things in Tech list for its Concentriq software, which digitizes pathology and leverages AI to enhance precision medicine. This recognition highlights its impact on addressing the rising global cancer burden and advancing diagnostic efficiency amid a shortage of pathologists. Concentriq, adopted by over 12,000 pathologists and major pharmaceutical and diagnostic companies, transforms traditional pathology by replacing microscopes with data-rich images. The platform enables deeper insights and supports advancements in precision therapies and diagnostics. CEO David West emphasized the platform’s role in improving cancer diagnosis and treatment, aligning with Proscia’s mission to revolutionize healthcare in the precision medicine era. Read more on Pathology News: https://lnkd.in/gtpXW7zf #digitalpathology #pathologynews

PathAI, a global leader in AI-driven digital pathology solutions, has announced the integration of advanced algorithms from leading companies including Deep Bio Inc., DoMore Diagnostics, Paige, and Visiopharm into its AISight1 Image Management System (IMS). These collaborations aim to enhance AISight’s functionality by embedding a diverse portfolio of AI tools directly into the platform, offering pathologists streamlined workflows, advanced diagnostic insights, and improved lab efficiency. Each partner brings unique innovations to AISight. Deep Bio’s DeepDx Prostate enhances prostate cancer diagnostics, while DoMore Diagnostics integrates its Histotype Px biomarker to support personalized cancer treatments. Paige and Visiopharm contribute expertise in diagnostic tools for cancer and precision pathology, expanding access to automated, AI-driven solutions for a broader audience. These partnerships highlight PathAI’s commitment to building a robust ecosystem that drives advancements in pathology and improves patient outcomes globally. Read more on Pathology News: https://lnkd.in/ewX74diC #digitalpathology #pathologynews

We’re delighted to welcome Cirdan Ltd as the newest partner in the Pathology News family! Check out their company and Digital Pathology LIS product showcase below: 🏢 Cirdan: https://lnkd.in/e6D63uHA 💻 LIS Showcase: https://lnkd.in/eSdFTpfQ Cirdan is dedicated to enhancing global patient well-being through innovative diagnostic solutions, revolutionizing laboratories worldwide with their streamlined, scalable, and automated systems. One of their standout products, the Cirdan Digital Pathology LIS, seamlessly integrates digital pathology and AI to help labs optimize workflows and achieve diagnostic efficiencies. With full LIS integration and support for a wide range of leading scanning vendors, it’s a perfect solution for digitizing cellular pathology services. Interested in learning more about Cirdan and their innovative offerings? Visit their product showcase on our site and request more information. #pathologynews #digitalpathology

Owkin and Proscia have partnered to advance colorectal cancer diagnosis using AI. Owkin’s MSIntuit® CRC v2, an advanced diagnostic tool, will integrate with Proscia’s Concentriq® software platform, becoming part of its precision medicine AI portfolio. This collaboration aims to help pathologists efficiently pre-screen patients with microsatellite stable (MSS) or proficient mismatch repair (pMMR) colorectal tumors, addressing the growing demand for MSI screening. MSIntuit CRC v2 builds on the success of its CE-IVD-certified predecessor, offering sensitivity comparable to traditional testing while reducing unnecessary tests for nearly half of patients. By integrating this AI diagnostic into major pathology labs, the partnership seeks to expand access to more efficient and accurate testing. Owkin and Proscia share a vision to transform precision medicine through AI, combining their expertise to streamline diagnostic workflows and improve patient outcomes. Read the full article on Pathology News: https://lnkd.in/eDhxtfXY #digitalpathology #pathologynews

This blog from 10x Genomics explores the transformative potential of single-cell sequencing (scRNA-seq) and multiomics in uncovering cellular heterogeneity. Unlike bulk RNA-seq these methods provide cell-specific insights, enabling the discovery of rare cell types, transient states, and intricate molecular mechanisms. They are reshaping research in fields like neurodevelopment, cancer, and immunology by offering high-resolution views of complex biological systems. Single-cell multiomics goes further by integrating transcriptomics with other data types, such as chromatin accessibility and protein expression, from the same cell. This holistic approach enhances accuracy, conserves resources, and reveals dynamic processes like immune responses or tumor heterogeneity with unprecedented clarity. Adopting single-cell sequencing involves familiar steps like sample preparation and RNA analysis but adds cell isolation and barcoding for individual resolution. By building on established workflows, this technology enables researchers to unlock deeper biological insights, driving innovations in diagnostics and treatments. Read the full article on Pathology News: https://lnkd.in/e5ng4RD4 #digitalpathology #pathologynews

Indica Labs just announced their latest application note on AI-powered slide quality control workflows for life science and clinical applications. The SlideQC BF algorithm detects common artifacts including tissue folds, out-of-focus areas, dust, air bubbles, and pen marks in H&E- and IHC-stained whole slide images. SlideQC BF is included in HALO AI for applications in the life sciences and available for deployment in HALO AP for clinical applications. Download the app note to learn more about how this powerful slide quality control algorithm can help enhance efficiency, improve the quality of diagnostic, research, and archival material, and future-proof labs. View and download the application note by following the link below: 👉 https://lnkd.in/eRvnPKfd #digitalpathology #pathologynews